Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...

Representative Jefferson Shreve (R-Indiana) recently bought shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). In a filing disclosed on March 09th, the Representative disclosed that they had ...

A month has gone by since the last earnings report for Vertex Pharmaceuticals (VRTX). Shares have added about 7.3% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

AbbVie, Danaher, Thermo Fisher Scientific, Cognizant Technology Solutions, and Vertex Pharmaceuticals are the five Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) yesterday and set a price target ...

The US pharmaceutical sector is experiencing a distinct trend never seen before with large American pharma companies continually looking for medicines in China.

BTIG analyst Mark Massaro lowered the firm’s price target on MaxCyte (MXCT) to $6 from $8 and keeps a Buy rating on the shares after its Q4 ...

We provide more details on some of the top companies in the Nasdaq 100 index that are dragging the QQQ ETF this year.

Renaissance Technologies' 13F reveals shifts in a $67.6B portfolio with notable changes in Palantir, Novo Nordisk, and NVIDIA ...

Dow Jones futures rose solidly early Wednesday, along with S&P 500 futures and Nasdaq futures. The CPI inflation report is due before the open.The stock market reversed sharply lower Tuesday morning ...

Vertex Pharmaceuticals has dominated the cystic fibrosis (CF) market and is now expanding into new, high-growth areas. The ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...